CLSD CLEARSIDE BIOMEDICAL INC revenue, earnings and financials

For the quarter ended September 30, 2025, CLEARSIDE BIOMEDICAL INC reported revenue of $201K (down 80.6% from a year earlier), net income of −$5.97M and diluted EPS of −$1.14; over the last four quarters revenue was $3.33M and net income −$26.0M; for the fiscal year ended December 2024 revenue was $1.66M, down 79.8% on the year before.

CLSD annual revenue and earnings

• Fiscal year ended Dec 2024: revenue $1.66M, gross profit n/a, operating income −$28.9M, net income −$34.4M (margin -2064.4%), EPS −$0.47
• Fiscal year ended Dec 2023: revenue $8.23M, gross profit n/a, operating income −$24.8M, net income −$32.5M (margin -394.9%), EPS −$0.53
• Fiscal year ended Dec 2022: revenue $1.33M, gross profit n/a, operating income −$30.3M, net income −$32.9M (margin -2482.8%), EPS −$0.55
• Fiscal year ended Dec 2021: revenue $29.6M, gross profit n/a, operating income −$627K, net income $376K (margin 1.3%), EPS $0.01

CLSD quarterly revenue and earnings

• Quarter ended Sep 30, 2025: revenue $201K (down 80.6% year over year), net income −$5.97M, EPS −$1.14
• Quarter ended Jun 30, 2025: revenue $492K (up 446.7% year over year), net income −$4.50M, EPS −$0.06
• Quarter ended Mar 31, 2025: revenue $2.33M (up 913.0% year over year), net income −$8.22M, EPS −$0.11
• Quarter ended Dec 31, 2024 (from the annual report): revenue $306K (down 95.2% year over year), net income −$7.31M, EPS $1.34
• Quarter ended Sep 30, 2024: revenue $1.04M (up 20.8% year over year), net income −$7.69M, EPS −$1.54
• Quarter ended Jun 30, 2024: revenue $90.0K (down 91.2% year over year), net income −$7.60M, EPS −$0.10
• Quarter ended Mar 31, 2024: revenue $230K (up 5650.0% year over year), net income −$11.8M, EPS −$0.17
• Quarter ended Dec 31, 2023 (from the annual report): revenue $6.35M (up 1822.7% year over year), net income −$4.83M, EPS −$0.08
• Quarter ended Sep 30, 2023: revenue $859K (up 222.9% year over year), net income −$9.27M, EPS −$0.15
• Quarter ended Jun 30, 2023: revenue $1.02M (up 165.1% year over year), net income −$9.11M, EPS −$0.15
• Quarter ended Mar 31, 2023: revenue $4.00K (down 98.8% year over year), net income −$9.28M, EPS −$0.15
• Quarter ended Dec 31, 2022 (from the annual report): revenue $330K (down 98.7% year over year), net income −$9.66M, EPS −$0.16
• Quarter ended Sep 30, 2022: revenue $266K (down 91.3% year over year), net income −$7.83M, EPS −$0.13
• Quarter ended Jun 30, 2022: revenue $384K (down 50.8% year over year), net income −$7.81M, EPS −$0.13
• Quarter ended Mar 31, 2022: revenue $347K (up 920.6% year over year), net income −$7.64M, EPS −$0.13
• Quarter ended Dec 31, 2021 (from the annual report): revenue $25.7M, net income $18.7M, EPS $0.33
• Quarter ended Sep 30, 2021: revenue $3.07M, net income −$4.89M, EPS −$0.08
• Quarter ended Jun 30, 2021: revenue $780K, net income −$6.10M, EPS −$0.11
• Quarter ended Mar 31, 2021: revenue $34.0K, net income −$7.35M, EPS −$0.13

CLSD cash flow, buybacks and dividends

• Fiscal year ended Dec 2024: operating cash flow −$24.7M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$18.1M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$13.4M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$10.7M, share buybacks n/a

CLSD balance sheet

• Sep 30, 2025: cash $6.80M, total assets $11.6M, total liabilities $65.6M, shareholders' equity −$54.0M
• Jun 30, 2025: cash $9.38M, total assets $15.3M, total liabilities $64.1M, shareholders' equity −$48.7M
• Mar 31, 2025: cash $13.6M, total assets $19.7M, total liabilities $65.6M, shareholders' equity −$45.9M
• Dec 31, 2024: cash $20.0M, total assets $25.1M, total liabilities $64.0M, shareholders' equity −$38.9M
• Sep 30, 2024: cash $13.9M, total assets $29.2M, total liabilities $64.0M, shareholders' equity −$34.8M
• Jun 30, 2024: cash $18.2M, total assets $33.9M, total liabilities $62.2M, shareholders' equity −$28.3M
• Mar 31, 2024: cash $35.4M, total assets $40.1M, total liabilities $62.0M, shareholders' equity −$21.8M
• Dec 31, 2023: cash $28.9M, total assets $34.0M, total liabilities $49.9M, shareholders' equity −$15.9M

What is CLSD's revenue?

CLEARSIDE BIOMEDICAL INC reported $3.33M of revenue over its last four quarters, through September 30, 2025.

Is CLSD profitable?

No. CLEARSIDE BIOMEDICAL INC lost $26.0M over the last four quarters.

What is CLSD's EPS?

Diluted earnings per share over the last four quarters were $0.03; −$1.14 in the latest quarter.

CLSD ownership and insider trades · All stocks